๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jinan
Clinical trial register · China

Clinical Trials in Jinan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Qilu Hospital of Shandong University114 Qianfoshan Hospital32 Shandong Cancer Hospital and Institute31 AstraZeneca26 Shandong University26
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Jinan

785 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study
NCT06731023HELICOBACTER PYLORI INFECTIONS
DrugsBismuth·Amoxicillin·Vonoprazan
Xiuli Zuo
Observational
30
Jinan
2025-01-01
Not yet open
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
NCT06643195AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
358
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2025-01-01
Recruiting
Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology
NCT07379281Bladder Cancer
Qilu Hospital of Shandong University
Observational
254
Jinan
2025-01-01
Recruiting
Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.
NCT07379268Bladder Cancer
Qilu Hospital of Shandong University
Observational
224
Jinan
2025-01-01
Recruiting
Multimodal Ultrasound in DBD Kidneys for Predicting Early Postoperative Renal Insufficiency Risk
NCT07090512Occurrence of Renal Dysfunction (GFR โ‰ค 60mL/(Minยท1.73m2)) in Renal Transplant Recipients Within One Year After Kidney Transplantation
Bei Wang
Observational
27
Jinan
2025-01-01
Not yet open
Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
NCT06717204HFrEF - Heart Failure With Reduced Ejection Fraction, Myocardial Infarction (MI)
DrugVericiguat
Qilu Hospital of Shandong University
Observational
210
Jinan
2025-01-01
Recruiting
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
NCT07732738Obesity
China-Japan Friendship Hospital
Not applicable
400
Xingtai, Zhengzhou, Baotou, Jinan, Datong, Kunming, Beijing
2025-01-01
Recruiting
Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.
NCT07379255Bladder Cancer
Qilu Hospital of Shandong University
Observational
266
Jinan
2025-01-01
Not yet open
Compound Danshen Dripping Pill for Diabetic Microvascular Angina
NCT06727890Diabetic Microvascular Angina
Qilu Hospital of Shandong University
Phase 4
162
Jinan
2025-01-01
Not yet open
Effect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery
NCT06712199Morbid Obesity
Yongtao Sun
Phase 4
124
Jinan
2025-01-01
Not yet open
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
NCT06774664IgA Nephropathy
DrugSCTC21C
Sinocelltech Ltd.
Phase 1/2
99
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning
2025-01
Recruiting
Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure
NCT07275554HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis, HBV (Hepatitis B Virus)
Qilu Hospital of Shandong University
Observational
100
Jinan
2024-12-31
Recruiting
Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06766578Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital
Phase 2
32
Jinan
2024-12-30
Recruiting
Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer
NCT06748352Early Gastric Cancer, Endoscopic Submucosal Dissection, Robot Surgery
Shandong University
Not applicable
50
Jinan
2024-12-30
Recruiting
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
NCT06613009Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Active, closed
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522MTAP-deleted NSCLC
DrugAnvumetostat
Amgen
Phase 2
61
Beijing, Fuzhou, Zhengzhou, Wuhan, Changsha, Changchun, Jinan, Shanghai
2024-12-26
Recruiting
Risk Factors for Complications After Cranioplasty
NCT06740773Cranioplasty, Postoperative Complications, Risk Assessment
Qilu Hospital of Shandong University
Observational
1,000
Chongqing, Xi'an, Jinan
2024-12-17
Recruiting
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
NCT06725381Solid Malignancies
DrugSKB571
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
138
Guangzhou, Nanning, Wuhan, Changsha, Nanjing, Jinan, Linyi, Chengdu
2024-12-17
Recruiting
Integrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer
NCT06702891Gastric Cardia Cancer
Qilu Hospital of Shandong University
Observational
20
Jinan
2024-12-17
Recruiting
An Intervention Study on Transcranial Photobiomodulation in Children With Attention Deficit Hyperactivity Disorder
NCT06685601ADHD - Attention Deficit Disorder With Hyperactivity
Qilu Hospital of Shandong University
Not applicable
60
Jinan
2024-12-16
Recruiting
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
NCT06753981Arterial Pulmonary Hypertension (PAH)
Qianfoshan Hospital
Observational
48
Jinan
2024-12-10
Recruiting
Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication
NCT06723197HELICOBACTER PYLORI INFECTIONS
DrugsTetracycline·Bismuth·Amoxicillin·Vonoprazan
Shandong University
Phase 4
330
Jinan
2024-12-10
Recruiting
Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
NCT07430579Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of Life
The Second Hospital of Shandong University
Not applicable
25
Jinan
2024-12-09
Recruiting
Comparision of Endoscopic Discectomy and Microdiscectomy for the Treatment of Lumbar Spinal Stenosis
NCT06719037Lumbar Spinal Stenosis
Qilu Hospital of Shandong University
Not applicable
324
Jinan
2024-12-08
Recruiting
A Study to Evaluate HB0034 in Healthy Chinese Adult Participants
NCT06716151Healthy
DrugHB0034
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1
60
Jinan
2024-12-06
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908Carcinoma, Non-Small-Cell Lung
DrugsJNJ-90301900·Durvalumab
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
Dongguan, Guangzhou, Jinan
2024-12-06
Active, closed
Balloon-Assisted Enteroscopic Treatment for Phytobezoar
NCT06877559Phytobezoar; Intestine
Shandong University
Observational
20
Jinan
2024-12-01
Recruiting
21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
NCT06891651Breast Cancer Metastatic, Breast Cancer Survival
Qilu Hospital of Shandong University
Observational
35
Jinan
2024-12-01
Not yet open
Lacticaseibacillus Rhamnosus LRa05 for Alleviating Allergic Rhinitis in Children
NCT06699537Allergic Rhinitis (AR)
Wecare Probiotics Co., Ltd.
Not applicable
70
Jinan
2024-12-01
Not yet open
Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery
NCT06663254Perioperative Volume Replacement, Hydroxyethyl Starch
Xiangya Hospital of Central South University
Phase 4
410
Zhengzhou, Changsha, Shenyang, Jinan, Xi'an, Beijing
2024-11-30
Active, closed
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855Open Angle Glaucoma, Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
Phase 3
345
Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang
2024-11-28
Recruiting
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
NCT06735326Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
DrugsFluzoparib·Carboplatin·Bevacizumab·Paclitaxel
Qilu Hospital of Shandong University
Phase 2
105
Jinan
2024-11-27
Not yet open
Qishenyiqi for Ventricular Remodeling After Myocardial Infarction
NCT06699407Chronic Stable Heart Failure
Qilu Hospital of Shandong University
Phase 4
210
Jinan
2024-11-20
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
Multimodal Prognostic Assessment of Acute Ischemic Stroke Patients With Atrial Fibrillation: a Prospective, Multicenter, Observational Study (IAT-CLOSURE)
NCT06548269Acute Ischemic Stroke, Atrial Fibrillation
Jinan Central Hospital
Observational
1,000
Jinan
2024-11-15
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
DrugsABSK061·ABSK043·Capox
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
Recruiting
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
NCT06617416NSCLC (Non-small Cell Lung Cancer)
DrugsSugemalimab·Cadonilimab
Akeso
Phase 3
560
Jinan
2024-11-12
Recruiting
Fufang Congrong Yizhi Capsules (FCYC) of Cognitive Impairment After Intracerebral Hemorrhage
NCT06673602Cognitive Impairment, Intracerebral Hemorrhage
Qinhuangdao Hospital of Traditional Chinese Medicine
Phase 4
200
Beijing, Qinhuangdao, Kaifeng, Jinan, Weifang, Kunming
2024-11-04
Active, closed
Microbial Community Characteristics in Intestinal Mucosal Tissue of Patients With CD
NCT06895772Crohn's Disease (CD)
Shandong University
Observational
50
Jinan
2024-11-01
Recruiting
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
NCT06819215Cancer, Neoplasms, Neoplasms, Breast, Tumor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 1/2
188
Jinan
2024-10-30
Recruiting
Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer
NCT06656949Endometrial Cancer
Qilu Hospital of Shandong University
Not applicable
42
Jinan
2024-10-30
Recruiting
Spironolactone Improved Children With Gene Mutations Related to NCOR
NCT06678685NCOR Gene Mutations, Spironolactone, ASD
Qilu Hospital of Shandong University
Phase 2/3
2
Jinan
2024-10-30
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Recruiting
Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
NCT06639256Safety, Tolerability, Efficacy
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
258
Jinan
2024-10-24
Recruiting
Neoadjuvant Therapy in Cervical Cancer
NCT06558682Uterine Cervical Neoplasms
Qilu Hospital of Shandong University
Not applicable
48
Jinan
2024-10-20
Recruiting
Study on Topping-off Technique for Treating LDD
NCT06650046Lumbar Degenerative Disease
Qianfoshan Hospital
Not applicable
100
Jinan
2024-10-18
Active, closed
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
NCT06640049Neoplasms, Rectal
DrugDostarlimab
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Active, closed
Mass Balance Clinical Trial of SIM0270
NCT06654791Healthy Participants
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
6
Jinan
2024-10-17
Recruiting
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
NCT06730373HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
DrugsTegafur Gimeracil Oteracil·Disitamab Vedotin·Trastuzumab·Oxaliplatin
Qilu Hospital of Shandong University
Phase 2
110
Zhengzhou, Binzhou, Dongying, Jinan, Jining, Liaocheng, Linyi, Qingdao
2024-10-17
Recruiting
A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors
NCT07135128Advanced Solid Tumor
Xiaorong Sun
Phase 1
20
Jinan
2024-10-14
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer
NCT07135102Metastatic Castration-Resistant Prostate Cancer Patients
Xiaorong Sun
Phase 1
40
Jinan
2024-10-14
Recruiting
Model-informed Individualized Treatment of Anti-infective Drugs
NCT06711562Osteoarticular Infections
Shandong University
Observational
300
Jinan
2024-10-12
Recruiting
Model-informed Individualized Treatment of Anti-Infective Drugs in Patients With Spinal Infections
NCT06711575Infectious Diseases of Spine
Shandong University
Observational
300
Jinan
2024-10-12
Not yet open
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
NCT06649448Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF
DrugsCarboplatin/cisplatin-etoposide·Efbemalenograstim alfa·Carboplatin·Paclitaxel
Shandong Cancer Hospital and Institute
Not applicable
200
Jinan
2024-10-10
Recruiting
A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology
NCT06662071Bladder Cancer
Qilu Hospital of Shandong University
Observational
293
Binzhou, Dezhou, Jinan, Jining, Liaocheng, Linyi, Qingdao, Taian
2024-10-01
By invitation
A Study of the Mechanisms by Which Mood and Sleep Disorders Interact
NCT07495189Sleep Disorder Insomnia Chronic
Qilu Hospital of Shandong University
Observational
200
Jinan
2024-10-01
Not yet open
Twice-per-weekSelinexor, 2 Days Melphalan
NCT06613035Acute Myeloid Leukemia
DrugsMelphalan·Busulfan·Selinexor·Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
126
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2024-09-30
Active, closed
Pulsed-Field Ablation With/Without Electrogram Mapping
NCT07541989Non-paroxysmal Atrial Fibrillation
Xu Liu
Not applicable
300
Wuhan, Changshu, Xuzhou, Jinan, Wenling, Yuhuan, Shanghai
2024-09-30
Recruiting
A Phase 2 Study of HB0017 in Psoriasis Patients
NCT06592274Psoriasis (PsO)
Huabo Biopharm Co., Ltd.
Phase 2
200
Bengbu, Guangzhou, Changsha, Wuxi, Zhenjiang, Changchun, Jinan, Jining
2024-09-30
Recruiting
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT06530251Hepatocellular Carcinoma
DrugsAK127·AK130·Bevacizumab biosimilar·Cadonilimab
Akeso
Phase 1/2
280
Beijing, Jinan
2024-09-24
Recruiting
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
NCT06616571Chemotherapy-Induced Febrile Neutropenia
DrugPEG-rhG-CSF
Qilu Pharmaceutical Co., Ltd.
Phase 4
336
Jinan
2024-09-19
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
Recruiting
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
NCT06759064Cancer of Stomach, Adenocarcinoma, Ascites, Malignant
Qilu Hospital of Shandong University
Phase 1/2
24
Jinan
2024-09-12
Recruiting
Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment
NCT06348420Gastroesophageal Reflux Disease
Qilu Hospital of Shandong University
Not applicable
74
Jinan
2024-09-10
Recruiting
Early Screening Cohort Study of Multiple Gastrointestinal Tumors
NCT07106424Early Detection of Cancer
Shandong Cancer Hospital and Institute
Observational
4,000
Jinan
2024-09-10
Recruiting
A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Recruiting
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
NCT06289751Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy
DrugsPaclitaxel-albumin·Cadonilimab·Cisplatin
Tongji Hospital
Phase 2
50
Wuhan, Jinan
2024-09-03
Active, closed
Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury
NCT06596798AKI
Qianfoshan Hospital
Observational
1,200
Jinan
2024-09-01
Active, closed
Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based on Explainable Deep Neural Networks and Therapeutic Drug Monitoring
NCT06596811AKI, Therapeutic Drug Monitoring (TDM)
Qianfoshan Hospital
Observational
1,200
Jinan
2024-09-01
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
An Artificial Intelligence System for ROSE of EUS-FNA Sample: a Prospective, Multicenter, Diagnostic Study.
NCT06718725The Malignant Lesions and Non-malignant Lesions of Pancreas, Bile Duct, Liver and Lymph Node
Qilu Hospital of Shandong University
Observational
236
Jinan
2024-09-01
Not yet open
Perioperative Smoking Cessation in Elderly Chinese Undergoing Spinal Fusion
NCT06578611Spinal Fusion
The Second Hospital of Shandong University
Observational
2,000
Jinan
2024-09
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
DrugsS095029·Pembrolizumab
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Recruiting
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
NCT06617936Unresectable Non-small Cell Lung Cancer
Hua Zhang
Phase 2
36
Jinan
2024-08-27
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
DrugsRamucirumab·Volrustomig·Pemetrexed·Carboplatin
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
By invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
GrandPharma (China) Co., Ltd.
Observational
100
Guangzhou, Jinan, Xiโ€™an, Beijing, Shanghai
2024-08-22
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
DrugsRiliprubart·IVIG
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jiazhuang, Jinan
2024-08-21
Recruiting
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
NCT06615193Advanced Solid Tumors, Refractory Lymphoma, Relapsed Hematologic Malignancy
DrugHDM2005
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
111
Zhengzhou, Suzhou, Xuzhou, Nanchang, Jinan, Hangzhou, Tianjing
2024-08-12
Recruiting
CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS)
NCT06516822Long-standing Persistent Atrial Fibrillation, Ablation
The First Affiliated Hospital with Nanjing Medical University
Not applicable
320
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Dalian, Jinan, Xiโ€™an
2024-07-31
Not yet open
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
NCT06500247The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Qilu Hospital of Shandong University
Phase 2
43
Jinan
2024-07-31
Recruiting
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06470191Primary Membranous Nephropathy
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
216
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanning, Nantong, Qingdao
2024-07-30
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Recruiting
A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia
NCT06972537Pneumonia
Shandong University
Not applicable
42
Jinan
2024-07-24
Recruiting
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
NCT06454578Carcinoma, Hepatocellular
Qilu Hospital of Shandong University
Phase 2
30
Jinan
2024-07-24
Recruiting
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
NCT07309185Stomach Neoplasms
Shandong Tumor Hospital
Phase 2
66
Jinan
2024-07-24
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
Hefei, Beijing, Lanzhou, Harbin, Changsha, Changchun, Jinan, Chengdu
2024-07-19
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang
2024-07-12
Recruiting
A Clinical Study of B007 in the Treatment of Pemphigus.
NCT06454357Pemphigus
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Recruiting
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
NCT06434610Platinum-resistant Recurrent Ovarian Cancer
DrugPaclitaxel
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2
90
Beijing, Bengbu, Changsha, Fuzhou, Guangzhou, Jinan, Kunming, Nanning
2024-07-11
Active, closed
Exploring the Efficacy of a Breathing Training Intervention in Patients With Emotionally Regulated Sleep Disorders
NCT07495423Sleep Disorder (Disorder), Mood Disorders
Qilu Hospital of Shandong University
Not applicable
188
Jinan
2024-07-11
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
NCT06024746Heart Failure
DrugsEmpagliflozin·Finerenone
Colorado Prevention Center
Phase 3
1,500
Guangzhou, Changsha, Jinan, Shanghai, Taiyuan, Xian City, Chengdu, Tianjin
2024-07-09
Recruiting
ARTEMIS-008๏ผšHS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
NCT06498479Small Cell Lung Cancer
DrugsHS-20093·Topotecan
Hansoh BioMedical R&D Company
Phase 3
460
Beijing, Harbin, Zhengzhou, Changchun, Shenyang, Jinan, Shanghai, Guangzhou
2024-07-04
Recruiting
Effects of Different Inhaled Oxygen Concentrations on Lung Function in Older Patients After Laparoscopic Gastrointestinal Surgery Under General Anesthesia
NCT06359106Oxygenation Index
China Medical University, China
Phase 4
1,176
Shenyang, Beijing, Chendu, Chifeng, Dalian, Harbin, Jinan, Kunming
2024-07-02
Recruiting
Comprehensive Clinical Evaluation Study of GLP-1RA
NCT06686134T2DM
LI YAN
Observational
492
Jinan
2024-07-01
Recruiting
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
NCT06447597Generalized Myasthenia Gravis
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Not yet open
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
NCT06500091Soft Tissue Sarcoma, Melanoma
DrugsTQB2916·Doxorubicin Hydrochloride·Penpulimab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Active, closed
Cohort Profile๏ผšThe Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart)
NCT06604091Adenomyosis, in Vitro Fertilization
The Second Hospital of Shandong University
Observational
2,241
Jinan
2024-06-30
Recruiting
Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study)
NCT06385379Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
90
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jinan, Kunming
2024-06-30
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Recruiting
Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations
NCT06479343Intracranial Arteriovenous Malformations
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
170
Guangzhou, Zhengzhou, Nanjing, Changchun, Shenyang, Jinan, Beijing, Chengdu
2024-06-27
Rows per page Showing 401–500 of 785
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/jinan?page=5

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 785 of those studies with a site in Jinan.

How many clinical trials are recruiting in Jinan?

488 of the 785 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 130 have not yet opened recruitment, 149 are active but closed to new participants, and 18 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.